Tag:
R&D
Latest Headlines
Latest Headlines
Capsugel launches Lipidex platform for greater oral stability, potency
Capsugel, continuing its recent expansion in the drug capsule manufacturing arena, this week launched its new platform Lipidex, which the company says offers greater stability and potency for oral drugs.
Teva grabs MicroDose respiratory biz with inhaled delivery platform
Teva Pharmaceuticals bought drug delivery company MicroDose Therapeutx this week, taking hold of its inhalation platforms for lung diseases.
AstraZeneca homes in on new HQ and research site in Cambridge
Over the next three years the pharma company plans to build a $500 million complex on an 11-acre site at the Cambridge BioMedical Campus.
BD, JDRF team up for artificial pancreas
As medical device companies the world over race to develop an artificial pancreas, the Juvenile Diabetes Research Foundation has teamed up with Becton Dickinson to combine insulin infusion with continuous glucose monitoring and improve the lives of diabetics.
HPV antibodies point researchers to high risk for oral cancer
With rates of oral cancer linked to HPV infection on the rise, a group of investigators has pinned down a new biomarker that can be used to identify high-risk patients.
Buzz on rare disease drugs puts ViroPharma in the M&A spotlight
ViroPharma's pipeline of drugs for rare diseases has reportedly stirred the interest of several pharma companies. And once word of the buyout buzz spread, the Exton, PA-based biotech's shares zoomed up 9% yesterday afternoon.
AstraZeneca picks Cambridge site as ground zero for R&D reinvention
Over the next three years the pharma company plans to build a $500 million complex on its new campus that will house its U.K. operations for biologics and small molecule research as well as the corporate staff now operating in London.
Siemens inks companion diagnostics deal with J&J
As Siemens banks on personalized medicine to help turn around its healthcare business, the technology giant said its new companion diagnostics deal with Johnson & Johnson is a step in the right direction.
Ambrx taps WuXi for HER2-targeting cancer drug
Thanks to some big-name deals over the past year, Ambrx could rake in nearly $1 billion in licensing for its antibody drug conjugates, but the company hasn't lost sight of its in-house development, now partnering with WuXi PharmaTech and a Chinese drugmaker to advance a breast cancer treatment.
Ichorcumab: the blood of the gods?
Index Ventures recently completed an $11 million Series A investment in XO1, an asset-centric company established with the sole objective of developing the monoclonal antibody ichorcumab under license from Cambridge University.
